BCL2L1 and pancreatic neoplasm: However, a number of other trials are underway [51] Some BclXL antisense strategies were tested against PC in the early part of this decade where Xu and co-workers showed that BclXL antisense oligonucleotides can suppress pancreatic tumor growth and also sensitize these cells to gemcitabine [52].